Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 3/20 | 0.82 |
| ▸ | BMP1 | P13497 | 15/20 | 0.66 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.59 |
| ▸ | MMP1 | P03956 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP7 | P09237 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350900 | 0.90 | MMP3 (1.00) | MMP3BMP1MEP1BMMP1MMP2 | |
| SCHEMBL6419046 | 0.81 | MMP3 (0.80) | MMP3BMP1MEP1BMMP1MMP2 | |
| SCHEMBL7008058 | 0.80 | BMP1 (1.00) | BMP1 | |
| SCHEMBL5184099 | 0.77 | MMP1 (0.79) | BMP1MEP1BMMP1MMP7MMP8 | |
| SCHEMBL7004497 | 0.77 | BMP1 (0.89) | BMP1 | |
| SCHEMBL7000638 | 0.76 | BMP1 (1.00) | BMP1 | |
| SCHEMBL6997496 | 0.76 | BMP1 (0.89) | MMP3BMP1MEP1B | |
| SCHEMBL7346818 | 0.76 | MMP3 (0.73) | MMP3BMP1MEP1BMMP1MMP2 | |
| SCHEMBL7003452 | 0.75 | BMP1 (0.89) | BMP1 | |
| SCHEMBL7004503 | 0.75 | BMP1 (1.00) | MMP3BMP1MEP1BMMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | HO WEN-BIN (US) | 2003-10-09 | — | — | US | disclosed |
| EP-1154992-A4 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN INC (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6506936-B1 | Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases | FIBROGEN, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1154992-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050390-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | MMP1, MMP13, COL14A1 | MMP3 5/4885BMP1 730/4885MEP1B 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.